Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Notes Payables: 2015-2018

Historic Notes Payables for Lineage Cell Therapeutics (LCTX) over the last 4 years, with Dec 2018 value amounting to $70,000.

  • Lineage Cell Therapeutics' Notes Payables fell 85.00% to $18,000 in Q1 2019 from the same period last year, while for Mar 2019 it was $18,000, marking a year-over-year decrease of 85.00%. This contributed to the annual value of $70,000 for FY2018, which is 53.95% down from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Notes Payables stood at $70,000 for FY2018, which was down 53.95% from $152,000 recorded in FY2017.
  • Lineage Cell Therapeutics' 5-year Notes Payables high stood at $833,000 for FY2016, and its period low was $70,000 during FY2018.
  • Moreover, its 3-year median value for Notes Payables was $152,000 (2017), whereas its average is $351,667.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Notes Payables surged by 776.84% in 2016 and then slumped by 81.75% in 2017.
  • Yearly analysis of 4 years shows Lineage Cell Therapeutics' Notes Payables stood at $95,000 in 2015, then spiked by 776.84% to $833,000 in 2016, then plummeted by 81.75% to $152,000 in 2017, then tumbled by 53.95% to $70,000 in 2018.